Abstract: Embodiments of an adapter, a system including the adapter, and methods of using the adapter may be for mixing a first substance and a second substance. The adapter may include a body having a first port configured to connect with a first container to receive a first substance, a second port configured to connect with a second container to receive a second substance, a third port configured to connect with a recipient container to output a mixture of the first substance and the second substance, and a mixing chamber having a first portion in communication with the first port and the second port and a second portion in communication with the third port. The adapter may further include a mixing pin inserted into the mixing chamber. In some embodiments, the mixing pin at least partially defines at least one microfluidic path for mixing the first substance and the second substance. In some embodiments, at least one of the first channel and the second channel are oriented offset of a central plane of the body.

Abstract: Embodiments of an adapter, a system including the adapter, and methods of using the adapter may be for mixing a first substance and a second substance. The adapter may include a body having a first port configured to connect with a first container to receive a first substance, a second port configured to connect with a second container to receive a second substance, a third port configured to connect with a recipient container to output a mixture of the first substance and the second substance, and a mixing chamber having a first portion in communication with the first port and the second port and a second portion in communication with the third port. The adapter may further include a mixing pin inserted into the mixing chamber. In some embodiments, the mixing pin at least partially defines at least one microfluidic path for mixing the first substance and the second substance. In some embodiments, at least one of the first channel and the second channel are oriented offset of a central plane of the body.

Abstract: Provided herein are methods, systems, and compositions for determining a base in a polynucleotide. In various aspects, the methods, systems, and compositions presented herein are useful for performing 4-base, 5-base, or 6-base sequencing of polynucleotide molecules, for example, from liquid biopsy samples or wherein the base is a low frequency mutation.

Abstract: A reinforcing system for a vessel that can contain water is described. The system includes a shell for containing water, the shell having one or more jets extending therethrough from an inside of the shell to an outside of the shell, and a structural support layer on an underside of the shell. The structural support layer can include: an inner layer of rigidizer applied to the underside of the shell, a central low density core, and an outer layer of rigidizer applied to the central low-density core. The structural support layer can extend from a bottom side of the underside of the shell, across at least one sidewall of the underside of the shell, and form at least one rib along the sidewall of the underside of the shell.

Abstract: Described herein is a method of purifying a silk fibroin preparation including preparing an aqueous silk fibroin solution having a concentration of greater than or equal to 5% w/v silk fibroin from the silk fibroin preparation, wherein the silk fibroin preparation includes a chaotropic salt; and exchanging the chaotropic salt from the silk fibroin solution at a pH below the isoelectric point of the silk fibroin, wherein the pH is between 2 and 5, replacing the chaotropic salt with a buffer comprising 10 to 300 mM of a second salt, or a combination thereof, to prepare the purified silk fibroin.

Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Abstract: The embodiments disclosed and embraced by the present invention include silk-based products useful in the treatment, diagnosis, palliation, and/or amelioration of ocular diseases or conditions of the eye including those of the structures of the eye and surrounding tissue. Such silk-based products may effect beneficial outcomes alone or in combination with therapeutic modalities, compounds or medicaments.

Abstract: Embodiments of the present disclosure include formulations of silk-based product (SBP) formulations and related methods of preparation and use in a variety of applications in the fields of human therapeutics, veterinary medicine, agriculture, and material science.

Abstract: Embodiments of the present disclosure include formulations of silk-based product (SBP) formulations and related methods of preparation and use in a variety of applications in the fields of human therapeutics, veterinary medicine, agriculture, and material science.

Abstract: The present disclosure includes formulations of processed silk and related methods of preparation and use in a variety of applications.

Abstract: The embodiments disclosed and embraced by the present invention include silk-based products useful in the treatment, diagnosis, palliation, and/or amelioration of ocular diseases or conditions of the eye including those of the structures of the eye and surrounding tissue. Such silk-based products may effect beneficial outcomes alone or in combination with therapeutic modalities, compounds or medicaments.

Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Abstract: The embodiments disclosed and embraced by the present invention include silk-based products useful in the treatment, diagnosis, palliation, and/or amelioration of ocular diseases or conditions of the eye including those of the structures of the eye and surrounding tissue. Such silk-based products may effect beneficial outcomes alone or in combination with therapeutic modalities, compounds or medicaments.

Abstract: Embodiments of the present disclosure include formulations of silk-based product (SBP) formulations and related methods of preparation and use in a variety of applications in the fields of human therapeutics, veterinary medicine, agriculture, and material science.

Abstract: Embodiments of the present disclosure include silk-based products and related methods of use in a variety of applications. Included are applications in the fields of medicine, veterinary medicine, agriculture, and material science.

Abstract: Various splice connector assemblies are disclosed. The splice connector assembly can include a connection unit mating a female and male terminals. The splice connector assembly can include an outer housing with an inner passage configured to receive the terminals. A first securing mechanism can be engaged with a first end of the outer housing and a second securing mechanism can be engaged with a second end of outer housing. The first and second securing mechanisms can each include a coupling nut engaged with the housing, a washer that is non-rotatably connected to the housing, and a sealing gland that comprises an aperture having a non-concentric cross sectional shape.

Abstract: Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

Abstract: Various interconnect assemblies are disclosed. The interconnect assembly can include an insert having a hook protrusion that fits into a slot of a receiving region. The hook protrusion can have a curved surface that helps the hook protrusion slide into a slot as the insert is rocked toward the receiving region to seat the insert in the receiving region. The receiving region can have a latch that snaps over a key portion of the insert to keep the insert seated in the receiving region.

Abstract: Various connection interfaces are disclosed. In some embodiments, the connection interface includes a receptacle and a connector. The receptacle can be configured to be positioned in the wall of an electrical device. The receptacle can comprise a first set of electrical contacts and a channel. The connector can be configured to be matingly engaged with the receptacle in an engaged state and to be separated from the receptacle in a disengaged state. The connector can comprise a second set of electrical contacts. Some embodiments are configured such that angled surfaces of the channel and boss interact as the connector is moved into engagement with the receptacle. This can guide the connector into the receptacle such that the first and second sets of electrical contacts are in electrical communication with each other.